The Evolving World of Oral SERDs: A Deep Dive into Patient Selection, Sequencing Strategies, and Emerging Data - Episode 5
A panelist discusses how real-world studies of elacestrant showed even better outcomes than clinical trials, with progression-free survival approaching 9 months, demonstrating the drug’s effectiveness in broader patient populations.
Real-World Evidence and Clinical Outcomes
Real-world studies typically show inferior outcomes compared to clinical trials due to older patients, increased comorbidities, and less stringent selection criteria. However, elacestrant demonstrated superior real-world performance compared to its clinical trial data, indicating exceptional drug activity and highlighting the heavily pretreated nature of the original study population. This unusual pattern speaks to both the drug’s efficacy and the challenging patient population studied.
Two real-world studies confirmed elacestrant’s clinical benefit, with progression-free survival approaching 9 months in patients without prior fulvestrant exposure receiving first- or second-line treatment. Even patients who had received prior fulvestrant achieved 6 to 8 months progression-free survival, exceeding clinical trial expectations. These results provide reassurance about elacestrant’s effectiveness across diverse patient populations.
The superior real-world outcomes offer confidence for treating patients who might not meet strict clinical trial criteria, including older adults and those with multiple comorbidities. This real-world evidence supports elacestrant’s broad applicability in clinical practice and suggests that the drug’s benefits extend beyond the carefully selected clinical trial populations to everyday clinical scenarios.